GlaxoSmithKline has joined other drugmakers in halting new clinical trials in Russia while still providing essential medicines to the country. Like others in the sector, it will push on with existing trials.
The war in Ukraine has affected hundreds of clinical trials there and in Russia, where pharmaceutical firms test new medicines on volunteers, often across many countries, before submitting the drugs to regulators for approval.
